{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:29:58Z","timestamp":1782563398114,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":543,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jfma.2012.07.044","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T21:02:14Z","timestamp":1350421334000},"page":"506-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment"],"prefix":"10.1016","volume":"113","author":[{"given":"Eric Chieh-Lung","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Jung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Wei","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2012.07.044_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardization of terminology of lower urinary tract function: report from the Standardization Sub-Committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.jfma.2012.07.044_bib2","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"issue":"5 Suppl. 1","key":"10.1016\/j.jfma.2012.07.044_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","article-title":"Definition and epidemiology of overactive bladder","volume":"60","author":"Wein","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.jfma.2012.07.044_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.urology.2006.03.035","article-title":"Epidemiologic survey of lower urinary tract symptoms in Japan","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jfma.2012.07.044_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/nau.20293","article-title":"Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women","volume":"25","author":"Zhang","year":"2008","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.jfma.2012.07.044_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00345-009-0490-1","article-title":"Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study","volume":"29","author":"Lee","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.jfma.2012.07.044_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jfma.2012.07.044_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","article-title":"Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score","volume":"77","author":"Homma","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.jfma.2012.07.044_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.urology.2005.09.035","article-title":"Translating overactive bladder questionnaires in 14\u00a0languages","volume":"67","author":"Acquardo","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jfma.2012.07.044_bib10","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jfma.2012.07.044_bib11","series-title":"Practical statistics for medical research","author":"Altman","year":"1992"},{"key":"10.1016\/j.jfma.2012.07.044_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.jfma.2012.07.044_bib13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.jfma.2012.07.044_bib14","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1464-410X.2005.05835.x","article-title":"An epidemiological survey of overactive bladder symptoms in Japan","volume":"96","author":"Homma","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.jfma.2012.07.044_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s001920170043","article-title":"The epidemiology of overactive bladder among females in Asia: a questionnaire survey","volume":"12","author":"Lapitan","year":"2001","journal-title":"Int Urogynecol J Pelvic Floor Dysfunc"},{"key":"10.1016\/j.jfma.2012.07.044_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000096337","article-title":"Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking","volume":"77","author":"Yu","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.jfma.2012.07.044_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.jfma.2012.07.044_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","article-title":"The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder","volume":"49","author":"Coyne","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.jfma.2012.07.044_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.jfma.2012.07.044_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor-which is the main mechanism of action?","volume":"43","author":"Andersson","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.jfma.2012.07.044_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1447-0756.2010.01493.x","article-title":"Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome","volume":"37","author":"Hsiao","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.jfma.2012.07.044_bib22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2006.11.010","article-title":"Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT)","volume":"28","author":"Garely","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jfma.2012.07.044_bib23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.jfma.2012.07.044_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1879-5226(10)60007-3","article-title":"Efficacy and adverse effects of solifenacin in the treatment of lower urinary tract symptoms in patients with overactive bladder","volume":"21","author":"Chen","year":"2010","journal-title":"Urol Sci"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664612003993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664612003993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T20:45:17Z","timestamp":1594759517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664612003993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0929664612003993"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2012.07.044","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2012.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}